1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ikonisys S.A.
  6. Summary
    ALIKO   FR00140048X2

IKONISYS S.A.

(ALIKO)
  Report
Real-time Euronext Paris  -  05/27 11:25:05 am EDT
2.660 EUR    0.00%
05/12Ikonisys S.A. with Evosciences Leasing GmbH to Support the Commercial Expansion in Europe and the USA of the Ikoniscope20
CI
05/04Ikonisys S.A. announced that it expects to receive funding from Negma Group Ltd.
CI
04/29Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
2.69(c) 2.69(c) 2.67(c) 2.66(c) 2.66(c) Last
1 206 151 1 201 Volume
0.00% 0.00% -0.74% -0.37% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2021 0,40 M 0,43 M 0,43 M
Net income 2021 -1,65 M -1,77 M -1,77 M
Net Debt 2021 1,50 M 1,61 M 1,61 M
P/E ratio 2021 -15,2x
Yield 2021 -
Sales 2022 1,20 M 1,29 M 1,29 M
Net income 2022 -1,80 M -1,93 M -1,93 M
Net Debt 2022 - - -
P/E ratio 2022 -16,6x
Yield 2022 -
Capitalization 25,2 M 27,0 M 27,0 M
EV / Sales 2021 66,8x
Capi. / Sales 2022 21,0x
Nbr of Employees -
Free-Float -
More Financials
Company
Ikonisys S.A. is specialized in the design, manufacture and marketing of medical diagnostic equipment. The company offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. Net sales break down by source of revenue as follows: - sales of maintenance services (70.4%); - sales of products (29.6%): sales of Ikoniscope instruments and the related software... 
More about the company
All news about IKONISYS S.A.
05/12Ikonisys S.A. with Evosciences Leasing GmbH to Support the Commercial Expansion in Euro..
CI
05/04Ikonisys S.A. announced that it expects to receive funding from Negma Group Ltd.
CI
04/29Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/29IKONISYS S A : publishes its Full-Year Financial Results for 2021 and provides an update o..
PU
02/21IKONISYS S A : Investors presentation
PU
02/21IKONISYS S A : Présentation investisseurs
PU
02/16Ikonisys SA Announces Preliminary Results of Sensitivity of Ikoniscope20 to Detect Rare..
CI
02/07Ikonisys SA Announces the Successfull Installation of the Ikoniscope20 At Tomalab, One ..
CI
02/01Ikonisys SA Announces the Appointment of Gabriel Plan as France Sales Director
CI
2021IKONISYS : Soft H1, but on track to achieve mid-term targets
AL
2021IKONISYS S.A. : Half-year report
CO
2021IKONISYS S.A. : Half-year results
CO
2021IKONISYS : Factoring in the revised commercialisation plans
AL
2021Ikonisys SA Names Manny Iglesias as ’ Sales Director for the US Market
CI
2021Initial Results of a Study, in Collaboration With the UConn School of Medicine, Highlig..
CI
More news
News in other languages on IKONISYS S.A.
05/12Ikonisys S.A. avec Evosciences Leasing GmbH pour soutenir l'expansion commerciale en Eu..
05/12IKONISYS S A : With Evosciences Leasing To Support The Commercial Expansion In Europe And ..
05/09IKONISYS SA (VON SPHENE CAPITAL GMBH : Buy
05/04IKONISYS S A : signe un accord de financement d'un montant nominal total pouvant aller jus..
04/29Ikonisys S.A. annonce ses résultats pour l'année complète se terminant le 31 décembre 2..
More news
Analyst Recommendations on IKONISYS S.A.
More recommendations
Chart IKONISYS S.A.
Duration : Period :
Ikonisys S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IKONISYS S.A.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,66 €
Average target price 8,45 €
Spread / Average Target 218%
EPS Revisions
Managers and Directors
Mario P. Crovetto Chief Executive Officer & Director
Mario Mauri Chairman
Roberto Rettani Director
Sector and Competitors